A dedicated clinic for people whose blood test says the cancer is back
A positive leftover-cancer blood test leaves patients frightened and their doctors unsure what to do. A specialist clinic could give them a plan and a trial.
The molecular relapse population is growing fast and falls between services: no visible disease, no standard therapy, high anxiety and low trial awareness. A named clinic — confirmatory retesting, sensitive imaging, psychological support, trial screening and structured follow-up — is a service-design intervention that could be evaluated like any other pathway.
- Dormant cells and minimal residual disease · After a 'successful' treatment, cells can sleep for years then relapse. We can barely detect them and cannot target them.
- Fragmented care and guideline gaps · Patients fall between specialists, wait for referrals and often do not get the treatment guidelines say they should.
- Patients lack understanding, navigation and agency · Most patients cannot understand their options, find trials, or push back, so decisions are made for them.
Pages like this
not linked directly; found by shared links- IdeaPatient navigation as a legal entitlement from the day of diagnosis
Shares Patients lack understanding, navigation and agency, Fragmented care and guideline gaps.
- IdeaPatients are told which trials they qualify for at every treatment decision, in writing
Shares AI trial matching & clinical decision support, Patients lack understanding, navigation and agency.
- IdeaBlunt the inflammation that wakes sleeping cancer cells
Shares Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing.
- IdeaFlush dormant cells out of bone marrow, then kill them
Shares Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing.
- IdeaDecision aids built into the record for every preference-sensitive cancer choice
Shares Patients lack understanding, navigation and agency, Fragmented care and guideline gaps.
- IdeaTake the blood test, and give the drug, at the right time of day
Shares Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing.
- IdeactDNA-guided adjuvant therapy in stage II-III melanoma
Shares Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing.
- IdeaDynamic consent with usage receipts
Shares AI trial matching & clinical decision support, Patients lack understanding, navigation and agency.